Navigation Links
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Date:8/6/2009

gnostics, biomedical research, translational research and molecular medicine applications. As an industry innovator in DNA detection technology, SEQUENOM's MassARRAY system allows a direct mass measurement of nucleic acids, providing unparalleled precision and quantification. On the diagnostics front, SEQUENOM is developing a comprehensive portfolio of prenatal test methods by combining the versatility of the MassARRAY system with the company's SEQureDx technology, which enables the detection of circulating cell-free fetal nucleic acids in a maternal blood sample. The company is also developing tests for oncology, infectious diseases and other disorders. The company was founded in 1994 and is headquartered in San Diego, California. SEQUENOM maintains a Web site at http://www.sequenom.com. to which SEQUENOM regularly posts copies of its press releases as well as additional information about SEQUENOM. Interested persons can subscribe on the SEQUENOM Web site to email alerts or RSS feeds that are sent automatically when SEQUENOM issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM((R)), AttoSense(TM), SEQureDx(TM), and MassARRAY((R)) are trademarks of SEQUENOM, Inc. All other trademarks and service marks are the property of their respective owners.

Note to Investors

As previously announced, SEQUENOM will hold a conference call to discuss the second quarter and six-month financial results today, August 6, 2009, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1-800-706-7749 and outside the U.S. 1-617-614-3474. A 30-day archive of the call can be accessed at http://ir.sequenom.com/.
'/>"/>

SOURCE SEQUENOM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Madison, Wis. Third Wave Technologies Inc. , a Madison ... and RNA analysis applications, has named Kay Napier to its ... marketing will bring marketing insight to Third Wave, according to ... reaching heathcare and women's markets in the promotion of products ...
... Wis. - Author Thomas Friedman calls it the ... gap. , ,Whatever the label, they are referring to ... the so-called STEM (Science, Technology, Engineering, and Mathematics) disciplines, ... impact the future of technology in the United States. ...
... - Following a flurry of discussion in the ... Hood-like" features has been released in Madison for public ... , ,The site, Jellyfish.com , is designed to ... and sellers than the search engines from Google, Yahoo!, ...
Cached Biology Technology:Napier joins board of Third Wave Technologies 2TechnoJungle to highlight learning, innovation 2Jellyfish launches comparative shopping website 2
(Date:4/17/2014)... One day about eight years ago, Katia Silvera ... and her father were on a field trip in a ... orchid they had never seen before. , Unable to identify ... The orchid turned out to be an unnamed species. ... silverarum . , "Lophiaris" is the genus name, comprising about ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... expression is the process whereby the genetic information ... such as proteins, which have numerous different functions ... an important intermediary during gene expression, by relating ... mechanisms involved in manufacturing proteins. , By ... molecules present in an organism at a given ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... Human resistance to a retrovirus that infected chimpanzees and ... be at least partially responsible for the susceptibility of ... by a team of researchers at Fred Hutchinson Cancer ... provide a better understanding of this modern pandemic infection ...
... has plummeted since a comprehensive program against smoking was ... the national Centers for Disease Control and Prevention’s Morbidity ... nearly 20% lower than the 2002 rate -- a ... for 2006 is the lowest on record (17.5%), and ...
... might serve as biofactories for the production of various ... inserted new genes into mushrooms. , "There has always ... a choice platform for the mass production of commercially ... John B. Swayne Chair in spawn science and professor ...
Cached Biology News:Ancient retrovirus sheds light on modern pandemic 2Ancient retrovirus sheds light on modern pandemic 3Smoking rate has plummeted in New York City 2Modified mushrooms may yield human drugs 2